Fact Meets Function

Researchers developed hybrid nanocarriers combining rigid and flexible components to deliver active peptides, including GHK-Cu, for potential antioxidant and anti-inflammatory effects in skin applications. The nanocarriers were evaluated in vitro for their ability to reduce oxidative stress and inflammatory markers in skin cell models. This is an in vitro study, representing early-stage research on nanoparticle formulation and delivery mechanisms.

This animal model study investigated how the Gly-His-Lys-D-Ala (GHK) peptide affects skin wound healing processes. The research examined the peptide’s effects on various biological mechanisms involved in wound regeneration in animal subjects. This is animal model-level evidence and does not establish direct applicability to human wound care.

This animal model study investigated whether intranasal administration of GHK peptide could reduce Alzheimer’s disease-related symptoms in 5xFAD transgenic mice, which exhibit amyloid pathology and cognitive decline. The researchers found that GHK peptide treatment attenuated both behavioral deficits and neuropathological features associated with Alzheimer’s disease in these mice. This is an animal model study and represents preclinical evidence that would require human clinical validation before any therapeutic applications could be considered.

Researchers investigated liposomes as delivery vehicles for GHK-Cu tripeptide to improve its cosmetic application potential through in vitro studies. The research evaluated how liposome formulations could enhance the stability and penetration of GHK-Cu, a copper-containing peptide used in skincare products. This was an in vitro study examining formulation properties rather than human or animal testing.